Precision Medicine Investment Landscape 2025 | LeverVenture

Precision medicine is not one market. It is a stack of five distinct businesses — sequencing, assays and companion diagnostics, bioinformatics and software, clinical decision support, and therapeutics — bolted together by a shared premise: that treatment should be matched to a patient's molecular profile rather than their diagnosis code alone. Each layer of that stack has its own cost structure, its own competitive dynamics, and its own trajectory toward or away from commoditization. Investors who treat "precision medicine" as a single category price all five layers as though they carried the same margin profile. They do not, and the gap between them is where the return actually sits.

The layer that generates the most headlines — novel targeted and cell-based therapeutics — is not where margin structurally concentrates. Margin concentrates where a company controls a scarce input the rest of the stack depends on: a regulatory approval, a proprietary dataset, or a workflow embedded deeply enough in clinical practice that switching cost becomes a real moat. Sequencing has largely lost that scarcity. Two of the other four layers are still fighting to keep it.

01Sequencing Has Already Commoditized

The cost of generating raw sequence data has fallen for two decades and continues to fall, and the competitive set that can generate that data at scale has widened accordingly. Sequencing-as-a-service is now closer to a manufacturing business than a technology business: differentiation comes from throughput, cost, and turnaround time, not from proprietary science. That is not a criticism of the companies operating there — it is simply the economic reality of a layer where the core technical barrier has been solved and widely licensed. Growth equity capital deployed purely into sequencing capacity is underwriting a manufacturing margin, not a precision medicine premium.

02Assays and Companion Diagnostics Hold a Regulatory Moat

One layer up, the picture changes. A companion diagnostic — the specific test required to determine whether a patient is eligible for a given targeted therapy — is typically developed and validated alongside the drug it pairs with, reviewed by regulators as part of that approval, and often protected by exclusivity tied to the therapy itself. That regulatory linkage is a genuine moat: a competitor cannot simply build a cheaper version of the test and take share, because the label specifies which test was validated against the trial data. This is the layer where scarcity is most durable, and where diligence should focus less on sequencing cost curves and more on the strength and duration of the regulatory tie to the paired therapy.

03Bioinformatics Is Splitting Into Two Different Businesses

Infrastructure: Pipelines, Storage, and Compute

One branch of the software layer is infrastructure — the pipelines, storage, and computation that turn raw sequence data into a processed file. This branch is increasingly standardized, built on well-understood open-source and cloud tooling, and, like sequencing, trending toward commoditized pricing. A company competing purely on infrastructure is competing on reliability and cost, and should be valued accordingly rather than priced as though it holds a durable technology advantage.

Insight: Curated Evidence That Compounds

The other branch is insight — proprietary variant classification databases, curated evidence linking specific mutations to specific treatment outcomes, and the years of accumulated clinical correlation that make one company's interpretation more trusted than another's. This branch competes on data assets that compound with scale: every additional case correctly classified makes the next classification more defensible, and that accumulated evidence base is genuinely difficult for a new entrant to replicate quickly, even with comparable computational resources. This is where this layer's real, durable value sits, and it is the branch worth the underwriting effort to distinguish from the infrastructure business sitting next to it on a pitch deck.

The question for this category is never "is precision medicine a good market." It is "which layer of this stack controls something scarce enough that volume cannot compete it away."

04Where the Stack Reconnects to the Patient

Clinical Decision Support Sits Closest to the Prescribing Decision

Clinical decision support tools — the layer that takes a diagnostic result and an evidence base and turns it into an actionable treatment recommendation at the point of care — captures value through workflow integration rather than raw data quality. A tool embedded in the electronic health record at the moment a clinician is choosing a therapy has a structural advantage over an equally accurate tool that requires a clinician to leave their workflow to consult it. This is a business built on distribution and habit as much as on algorithmic quality, and it rewards patient, workflow-native go-to-market execution over pure technical differentiation.

Therapeutics Capture the Largest Dollars and the Largest Risk

Therapeutics remain the layer with the largest addressable revenue per approved product, and the largest binary risk: a single trial failure can erase years of value creation in a way that a diagnostics or software business rarely experiences at the same magnitude. The other four layers of the stack generate revenue whether or not any individual therapeutic succeeds, which is part of why growth equity investors increasingly look for diversified exposure across the stack rather than concentrated bets on single therapeutic assets.

There is also a structural relationship worth naming: every layer below therapeutics in this stack exists in large part to make a therapeutics company's own commercial case, by identifying the patients that specific drug can help and by embedding the recommendation to prescribe it into a clinician's workflow. A therapeutics investment thesis that ignores whether the diagnostic and decision-support infrastructure exists to actually find and treat the eligible population is incomplete, regardless of how strong the clinical data looks in isolation.

05Where Margin Sits Across the Stack

06How to Position Across the Stack

Growth equity investors underwriting precision medicine should map any target company explicitly to one or more of these five layers before evaluating growth rate or total addressable market, because the answer to "is this a good business" depends entirely on which layer the company actually occupies. A fast-growing sequencing company on razor-thin, commoditizing margins is a different underwriting problem than a slower-growing diagnostics company with a defensible regulatory tie to an approved therapy. The stack, not the category label, is the right unit of analysis. For the clinical-access consequences of where testing sits in this stack, see our note on the diagnostic bottleneck in precision oncology, and for how AI is changing the decision-support layer specifically, see AI in digital health diagnostics.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.